Surgery Partners, Inc.

NasdaqGS:SGRY Voorraadrapport

Marktkapitalisatie: US$2.9b

Surgery Partners Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Surgery Partners is de winst gegroeid met een gemiddeld jaarlijks percentage van 37.5%, terwijl de Healthcare industrie de winst jaarlijks groeide met 5.4%. De inkomsten zijn gegroeid met een gemiddelde van 11.2% per jaar.

Belangrijke informatie

37.5%

Groei van de winst

52.5%

Groei van de winst per aandeel

Healthcare Groei van de industrie8.5%
Inkomstengroei11.2%
Rendement op eigen vermogen3.0%
Nettomarge-2.0%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt

Nov 11
Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt

Market Cool On Surgery Partners, Inc.'s (NASDAQ:SGRY) Revenues

Oct 24
Market Cool On Surgery Partners, Inc.'s (NASDAQ:SGRY) Revenues

Surgery Partners (NASDAQ:SGRY) Has Some Way To Go To Become A Multi-Bagger

Oct 05
Surgery Partners (NASDAQ:SGRY) Has Some Way To Go To Become A Multi-Bagger

Surgery Partners, Inc. (NASDAQ:SGRY) Soars 25% But It's A Story Of Risk Vs Reward

Jul 25
Surgery Partners, Inc. (NASDAQ:SGRY) Soars 25% But It's A Story Of Risk Vs Reward

Here's Why Surgery Partners (NASDAQ:SGRY) Has A Meaningful Debt Burden

Jul 13
Here's Why Surgery Partners (NASDAQ:SGRY) Has A Meaningful Debt Burden

Slowing Rates Of Return At Surgery Partners (NASDAQ:SGRY) Leave Little Room For Excitement

Jun 21
Slowing Rates Of Return At Surgery Partners (NASDAQ:SGRY) Leave Little Room For Excitement

We Think Shareholders Are Less Likely To Approve A Pay Rise For Surgery Partners, Inc.'s (NASDAQ:SGRY) CEO For Now

May 31
We Think Shareholders Are Less Likely To Approve A Pay Rise For Surgery Partners, Inc.'s (NASDAQ:SGRY) CEO For Now

Surgery Partners, Inc.'s (NASDAQ:SGRY) Share Price Matching Investor Opinion

Apr 24
Surgery Partners, Inc.'s (NASDAQ:SGRY) Share Price Matching Investor Opinion

Surgery Partners' (NASDAQ:SGRY) Returns Have Hit A Wall

Mar 18
Surgery Partners' (NASDAQ:SGRY) Returns Have Hit A Wall

Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt

Feb 27
Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt

The Price Is Right For Surgery Partners, Inc. (NASDAQ:SGRY)

Dec 19
The Price Is Right For Surgery Partners, Inc. (NASDAQ:SGRY)

Returns Are Gaining Momentum At Surgery Partners (NASDAQ:SGRY)

Oct 26
Returns Are Gaining Momentum At Surgery Partners (NASDAQ:SGRY)

Does Surgery Partners (NASDAQ:SGRY) Have A Healthy Balance Sheet?

Sep 17
Does Surgery Partners (NASDAQ:SGRY) Have A Healthy Balance Sheet?

Are Investors Undervaluing Surgery Partners, Inc. (NASDAQ:SGRY) By 35%?

Aug 26
Are Investors Undervaluing Surgery Partners, Inc. (NASDAQ:SGRY) By 35%?

The Return Trends At Surgery Partners (NASDAQ:SGRY) Look Promising

Jul 21
The Return Trends At Surgery Partners (NASDAQ:SGRY) Look Promising

Surgery Partners, Inc.'s (NASDAQ:SGRY) Shareholders Might Be Looking For Exit

Jun 15
Surgery Partners, Inc.'s (NASDAQ:SGRY) Shareholders Might Be Looking For Exit

A Look At The Intrinsic Value Of Surgery Partners, Inc. (NASDAQ:SGRY)

May 26
A Look At The Intrinsic Value Of Surgery Partners, Inc. (NASDAQ:SGRY)

There's Been No Shortage Of Growth Recently For Surgery Partners' (NASDAQ:SGRY) Returns On Capital

Apr 14
There's Been No Shortage Of Growth Recently For Surgery Partners' (NASDAQ:SGRY) Returns On Capital

Surgery Partners (NASDAQ:SGRY) Has A Somewhat Strained Balance Sheet

Mar 24
Surgery Partners (NASDAQ:SGRY) Has A Somewhat Strained Balance Sheet

Surgery Partners, Inc. (NASDAQ:SGRY) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jan 24
Surgery Partners, Inc. (NASDAQ:SGRY) Shares Could Be 50% Below Their Intrinsic Value Estimate

We Think Surgery Partners (NASDAQ:SGRY) Is Taking Some Risk With Its Debt

Sep 26
We Think Surgery Partners (NASDAQ:SGRY) Is Taking Some Risk With Its Debt

The Returns On Capital At Surgery Partners (NASDAQ:SGRY) Don't Inspire Confidence

Aug 15
The Returns On Capital At Surgery Partners (NASDAQ:SGRY) Don't Inspire Confidence

Surgery Partners GAAP EPS of -$0.21 misses by $0.07, revenue of $615.4M misses by $3.61M

Aug 02

Surgery Partners And Alternative Near Cap-Gain Portfolio Wealth Builders

Jul 02

Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt

Jun 27
Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt

Opbrengsten en kosten

Hoe Surgery Partners geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqGS:SGRY Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 242,985-611240
30 Jun 242,889-341310
31 Mar 242,79511220
31 Dec 232,743-121210
30 Sep 232,715-341290
30 Jun 232,662-541100
31 Mar 232,609-921050
31 Dec 222,539-551020
30 Sep 222,442-311010
30 Jun 222,381-291080
31 Mar 222,309-381070
31 Dec 212,225-811040
30 Sep 212,163-861010
30 Jun 212,100-1351000
31 Mar 211,932-1501010
31 Dec 201,860-156970
30 Sep 201,829-179970
30 Jun 201,785-132920
31 Mar 201,856-119900
31 Dec 191,831-110890
30 Sep 191,805-238870
30 Jun 191,786-243870
31 Mar 191,777-241900
31 Dec 181,772-238940
30 Sep 181,732-122840
30 Jun 181,597-125890
31 Mar 181,443-102790
31 Dec 171,312-79690
30 Sep 171,159-22710
30 Jun 171,1357600
31 Mar 171,13914560
31 Dec 161,1219550
30 Sep 161,0799600
30 Jun 161,0399580
31 Mar 169811560
31 Dec 159361560
30 Sep 15855-70460
30 Jun 15696-73420
31 Mar 15544-69360
31 Dec 14394-66310
31 Dec 13279-9260

Kwaliteitswinsten: SGRY is momenteel verliesgevend.

Groeiende winstmarge: SGRY is momenteel verliesgevend.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: SGRY is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 37.5% per jaar verminderd.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van SGRY over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: SGRY is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Healthcare industrie ( 10.3% ).


Rendement op eigen vermogen

Hoge ROE: SGRY heeft een negatief Return on Equity ( 2.98% ), omdat het momenteel verliesgevend is.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden